Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Injection site pain · hormone‐sensitive prostate cancer

Degarelix probably leads to higher injection site pain compared with standard androgen suppression therapy (moderate certainty).

1 finding from 1 review

Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes only
RR 15.68 [7.41, 33.17]
8 studies · 2670 participants
Moderate